Although the urinary loss of calories by SGLT2-Is causes only modest decreases in body weight, these drugs are able to especially shrink the visceral fat depots in obese T2DM patients [190,191]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.